Abstract
Harringtonine (HT) and homoharringtonine (HHT), alkaloid esters isolated from the genus Cephalotaxus, exhibit antitumor activity. A semisynthetic HHT has been approved for treatment of chronic myelogenous leukemia. In addition to antileukemic activity, HT and HHT are reported to possess potent antiviral activity. In this study, we investigated the effects of HT and HHT on replication of varicella-zoster virus (VZV) in vitro. HT and HHT, but not their biologically inactive parental alkaloid cephalotaxine (CET), significantly inhibited replication of recombinant VZV-pOka luciferase. Furthermore, HT and HHT, but not CET, strongly induced down-regulation of VZV lytic genes and exerted potent antiviral effects against a VZV clinical isolate. The collective data support the utility of HT and HHT as effective antiviral candidates for treatment of VZV-associated diseases.
Article PDF
Similar content being viewed by others
References
Arvin, A.M. 1996. Varicella-zoster virus. Clin. Microbiol. Rev. 9, 361–381.
Arvin, A.M. 2002. Antiviral therapy for varicella and herpes zoster. Semin. Pediatr. Infect. Dis. 13, 12–21.
Arvin, A. and Gilden, D. 2013. Varicella-zoster virus, pp. 2015–2057. In Knipe, D.M. and Howley, P.M. (eds.), Fields virology, Philadelphia (Pennsylvania): Lippincott Williams & Wilkins.
Bae, S., Kim, S.Y., Do, M.H., Lee, C.H., and Song, Y.J. 2017. 1,2,3,4,6-penta-O-galloyl-ß-D-glucose, a bioactive compound in Elaeocarpus sylvestris extract, inhibits varicella-zoster virus replication. Antiviral Res. 144, 266–272.
Bae, S. and Song, Y.J. 2017. Inhibition of varicellazoster virus replication by an ethanol extract of Lysimachia mauritiana. Mol. Med. Rep. 15, 3847–3851.
Cao, J., Forrest, J.C., and Zhang, X. 2015. A screen of the NIH clinical collection small molecule library identifies potential anticoronavirus drugs. Antiviral Res. 114, 1–10.
Chen, R., Guo, L., Chen, Y., Jiang, Y., Wierda, W.G., and Plunkett, W. 2011. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117, 156–164.
Cohen, J.I., Brunell, P.A., Straus, S.E., and Krause, P.R. 1999. Recent advances in varicella-zoster virus infection. Ann. Intern. Med. 130, 922–932.
Fresno, M., Jimenez, A., and Vazquez, D. 1977. Inhibition of translation in eukaryotic systems by harringtonine. Eur. J. Biochem. 72, 323–330.
Gnann Jr, J.W. 2007. Antiviral therapy of varicella-zoster virus infections. In Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., and Yamanishi, K. (eds.), Human herpesviruses: Biology, therapy, and immunoprophylaxis, Cambridge, UK.
Huang, M.T. 1975. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol. Pharmacol. 11, 511–519.
Ida, M., Kageyama, S., Sato, H., Kamiyama, T., Yamamura, J., Kurokawa, M., Morohashi, M., and Shiraki, K. 1999. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res. 40, 155–166.
Jeon, J.S., Won, Y.H., Kim, I.K., Ahn, J.H., Shin, O.S., Kim, J.H., and Lee, C.H. 2016. Analysis of single nucleotide polymorphism among varicella-zoster virus and identification of vaccine-specific sites. Virology 496, 277–286.
Jia, K., Yuan, Y., Liu, W., Liu, L., Qin, Q., and Yi, M. 2018. Identification of inhibitory compounds against Singapore grouper iridovirus infection by cell viability-based screening assay and droplet digital PCR. Mar. Biotechnol. (NY) 20, 35–44.
Kaur, P., Thiruchelvan, M., Lee, R.C., Chen, H., Chen, K.C., Ng, M.L., and Chu, J.J. 2013. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob. Agents Chemother. 57, 155–167.
Kim, J.E., Kim, S.Y., Lim, S.Y., Kieff, E., and Song, Y.J. 2014. Role of Ca2+/calmodulin-dependent kinase II-IRAK1 interaction in LMP1-induced NF-kappaB activation. Mol. Cell. Biol. 34, 325–334.
Lu, S. and Wang, J. 2014. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J. Hematol. Oncol. 7, 2.
Morfin, F., Thouvenot, D., De Turenne-Tessier, M., Lina, B., Aymard, M., and Ooka, T. 1999. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicellazoster virus resistant to acyclovir. Antimicrob. Agents Chemother. 43, 2412–2416.
Powell, R.G., Weisleder, D., and Smith Jr, C.R. 1972. Antitumor alkaloids for Cephalataxus harringtonia: Structure and activity. J. Pharm. Sci. 61, 1227–1230.
Quintas-Cardama, A., Kantarjian, H., and Cortes, J. 2009. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa2009. Cancer 115, 5382–5393.
Romero, M.R., Serrano, M.A., Efferth, T., Alvarez, M., and Marin, J.J. 2007. Effect of cantharidin, cephalotaxine and homoharringtonine on “in vitro” models of hepatitis B virus (HBV) and bovine viral diarrhoea virus (BVDV) replication. Planta Med. 73, 552–558.
Tujebajeva, R.M., Graifer, D.M., Matasova, N.B., Fedorova, O.S., Odintsov, V.B., Ajtkhozhina, N.A., and Karpova, G.G. 1992. Selective inhibition of the polypeptide chain elongation in eukaryotic cells. Biochim. Biophys. Acta 1129, 177–182.
Zhang, Z., Rowe, J., Wang, W., Sommer, M., Arvin, A., Moffat, J., and Zhu, H. 2007. Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system. J. Virol. 81, 9024–9033.
Zhou, D.C., Zittoun, R., and Marie, J.P. 1995. Homoharringtonine: An effective new natural product in cancer chemotherapy. Bull. Cancer 82, 987–995.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, JE., Song, YJ. Anti-varicella-zoster virus activity of cephalotaxine esters in vitro. J Microbiol. 57, 74–79 (2019). https://doi.org/10.1007/s12275-019-8514-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-019-8514-z